Clinical trials
Diabetes Mellitus trials in Hong Kong with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Recruiting | 6 |
| Unknown status | 4 |
| Not yet recruiting | 2 |
| Active, not recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| The University of Hong Kong | 7 |
| Asia Diabetes Foundation | 6 |
| The Hong Kong Polytechnic University | 6 |
| Chinese University of Hong Kong | 5 |
| Duk-Woo Park, MD | 1 |
| Education University of Hong Kong | 1 |
| Elaine Chow | 1 |
| Hong Kong Metropolitan University | 1 |
| Juliana CN Chan | 1 |
| Lee's Pharmaceutical Limited | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Diabetes Mellitus | 31 |
| Diabetes Mellitus, Type 2 | 4 |
| Hypertension | 4 |
| Obesity | 4 |
| Glucose Intolerance | 3 |
| Non-alcoholic Fatty Liver Disease | 2 |
| Alcoholism | 1 |
| Alopecia | 1 |
| Arthritis, Psoriatic | 1 |
| Atherosclerosis | 1 |
Trials
Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.